Mr. Shallcross was appointed as the Company’s CEO on December 6, 2018 and has served as the Company’s CFO, Treasurer and Secretary since joining the Company in June 2015. Mr. Shallcross brings to the Company operational, financial and international biotech industry experience, as well as an established track record at leading the financial development and strategy for several publicly traded biotech companies. From May 2013 through May 2015, Mr. Shallcross served as EVP and CFO of Nuo Therapeutics, Inc. (formerly Cytomedix, Inc. From July 2011 to March 2012, Mr. Shallcross was Acting CFO of Senseonics, a privately-held medical device company located in Germantown, MD. He served as the CFO and Treasurer of Vanda Pharmaceuticals, Inc., for four years leading the company through its successful IPO and follow-on offering. He holds an MBA from the University of Chicago’s Booth School of Business and a Bachelor of Science degree in Accounting from the University of Illinois, Chicago.